This study is for people with a specific type of advanced pancreatic cancer called Metastatic Pancreatic Ductal Adenocarcinoma (PDAC). It's testing a new drug named quemliclustat along with standard chemotherapy drugs, nab-paclitaxel and gemcitabine, against a placebo (a fake treatment) and those same drugs. The goal is to see which combination helps patients live longer.

Eligibility: Participants need to have confirmed metastatic PDAC and not have received treatment for it before. Some treatments like radiation or biliary stent placement are allowed under certain conditions. Patients should have a good performance status and measurable tumor(s) that haven't been treated with radiation before.

Exclusion: Patients with other severe health issues or history of brain involvement by cancer are not eligible. Previous treatments like CD73 inhibitors are also a disqualifier.

• Participation may involve several visits and tests to monitor health and treatment effects.
• Potential benefits include contributing to cancer research and possibly extending life expectancy.
• Risks may involve side effects from treatment, which will be monitored closely.